Home
Virus
Gene
Disease
Dataset
Download
Help
 
Virus Dataset Sample Info

> Dataset: 23114756 Search Result


Summary
Item Summary
Project 23114756
Virus Name HBV
Sample Number 91
Disease HBV infection
Country

Sample
ID Sample ID Age Gender Origin Detail
1 2 View
2 3 View
3 4 View
4 92 View
5 13 View
6 18 View
7 21 View
8 22 View
9 29 View
10 31 View
11 32 View
12 33 View
13 34 View
14 37 View
15 40 View
16 49 View
17 50 View
18 52 View
19 55 View
20 58 View
21 90 View
22 89 View
23 61 View
24 70 View
25 76 View
26 80 View
27 1 View
28 8 View
29 9 View
30 11 View
31 83 View
32 12 View
33 14 View
34 15 View
35 20 View
36 28 View
37 35 View
38 38 View
39 39 View
40 41 View
41 51 View
42 63 View
43 65 View
44 78 View
45 79 View
46 85 View
47 5 View
48 6 View
49 19 View
50 23 View
51 36 View
52 42 View
53 43 View
54 44 View
55 87 View
56 82 View
57 46 View
58 48 View
59 54 View
60 56 View
61 57 View
62 59 View
63 64 View
64 88 View
65 66 View
66 71 View
67 72 View
68 74 View
69 86 View
70 81 View
71 7 View
72 10 View
73 16 View
74 17 View
75 24 View
76 25 View
77 26 View
78 91 View
79 27 View
80 84 View
81 30 View
82 45 View
83 47 View
84 53 View
85 60 View
86 67 View
87 68 View
88 69 View
89 73 View
90 75 View
91 77 View

Literature
Item Summary
PMID 23114756
Title Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Abstract We sought to determine the prevalence of hepatitis B virus (HBV) lamivudine (LAM)-resistant minority variants in subjects who once received LAM but had discontinued it prior to virus sampling. We performed direct PCR Sanger sequencing and ultradeep pyrosequencing (UDPS) of HBV reverse transcriptase (RT) of plasma viruses from 45 LAM-naive subjects and 46 LAM-experienced subjects who had discontinued LAM a median of 24 months earlier. UDPS was performed to a depth of approximately 3,000 reads per nucleotide. Minority variants were defined as differences from the Sanger sequence present in >/=0.5% of UDPS reads in a sample. Sanger sequencing identified >/=1 LAM resistance mutations (rtL80I/V, rtM204I, and rtA181T) in samples from 5 (11%) of 46 LAM-experienced and none of 45 LAM-naive subjects (0%; P = 0.06). UDPS detected >/=1 LAM resistance mutations (rtL80I/V, rtV173L, rtL180M, rtA181T, and rtM204I/V) in 10 (22%) of the 46 LAM-experienced subjects, including 5 in whom LAM resistance mutations were not identified by Sanger sequencing. Overall, LAM resistance mutations were more likely to be present in LAM-experienced (10/46, 22%) than LAM-naive subjects (0/45, 0%; P = 0.001). The median time since LAM discontinuation was 12.8 months in the 10 subjects with a LAM resistance mutation compared to 30.5 months in the 36 LAM-experienced subjects without a LAM resistance mutation (P < 0.001). The likelihood of detecting a LAM resistance mutation was significantly increased using UDPS compared to Sanger sequencing and was inversely associated with the time since LAM discontinuation.